From experimental studies in rats with monocrotalin induced pulmonary hypertension, it appears that SGLT2 inhibitors lower pulmonary pressure by attenuating pulmonary vascular remodeling (160, 161). The gene discussed is SLC5A2; the disease is pulmonary arterial hypertension.